Last reviewed · How we verify
Metazepium Iodide — Competitive Intelligence Brief
phase 2
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Metazepium Iodide (BUZEPIDE METIODIDE). Metazepine iodide is thought to work by interacting with specific biological pathways, but the exact mechanism is unknown.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Metazepium Iodide TARGET | BUZEPIDE METIODIDE | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Metazepium Iodide CI watch — RSS
- Metazepium Iodide CI watch — Atom
- Metazepium Iodide CI watch — JSON
- Metazepium Iodide alone — RSS
Cite this brief
Drug Landscape (2026). Metazepium Iodide — Competitive Intelligence Brief. https://druglandscape.com/ci/buzepide-metiodide. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing